Free Trial

Achieve Life Sciences (ACHV) Competitors

Achieve Life Sciences logo
$2.83 +0.04 (+1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$2.84 +0.02 (+0.53%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACHV vs. MYGN, VSTM, EBS, LXRX, XOMA, CBIO, VNDA, CDXS, IRWD, and SGMO

Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry.

Achieve Life Sciences vs. Its Competitors

Myriad Genetics (NASDAQ:MYGN) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Myriad Genetics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Achieve Life Sciences has a net margin of 0.00% compared to Myriad Genetics' net margin of -47.45%. Myriad Genetics' return on equity of -5.17% beat Achieve Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-47.45% -5.17% -3.44%
Achieve Life Sciences N/A -193.49%-116.68%

Myriad Genetics currently has a consensus price target of $12.45, suggesting a potential upside of 88.42%. Achieve Life Sciences has a consensus price target of $14.67, suggesting a potential upside of 418.26%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21
Achieve Life Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50

Achieve Life Sciences has lower revenue, but higher earnings than Myriad Genetics. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$837.60M0.73-$127.30M-$4.28-1.54
Achieve Life SciencesN/AN/A-$39.83M-$1.46-1.94

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 2.4% of Myriad Genetics shares are held by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Myriad Genetics had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 7 mentions for Myriad Genetics and 5 mentions for Achieve Life Sciences. Myriad Genetics' average media sentiment score of 1.17 beat Achieve Life Sciences' score of 0.54 indicating that Myriad Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Achieve Life Sciences
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Myriad Genetics beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACHV vs. The Competition

MetricAchieve Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$144.63M$2.64B$5.77B$9.93B
Dividend YieldN/A49.35%6.67%4.52%
P/E Ratio-1.9423.0375.6026.68
Price / SalesN/A752.40555.18213.69
Price / CashN/A169.7737.1158.92
Price / Book4.645.5011.446.09
Net Income-$39.83M$32.95M$3.28B$266.14M
7 Day Performance-5.03%2.69%0.84%0.27%
1 Month Performance8.02%7.87%7.15%4.13%
1 Year Performance-31.97%0.79%59.65%23.93%

Achieve Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACHV
Achieve Life Sciences
2.4134 of 5 stars
$2.83
+1.4%
$14.67
+418.3%
-34.4%$144.63MN/A-1.9420Short Interest ↑
High Trading Volume
MYGN
Myriad Genetics
3.7762 of 5 stars
$5.89
-2.2%
$12.45
+111.5%
-73.2%$560.13M$837.60M-1.382,700Positive News
VSTM
Verastem
2.2314 of 5 stars
$8.98
-1.1%
$13.29
+47.9%
+332.8%$558.83M$10K-2.7450
EBS
Emergent Biosolutions
4.826 of 5 stars
$9.17
-0.7%
$14.33
+56.3%
+2.9%$492.43M$1.04B3.742,420Positive News
Analyst Forecast
LXRX
Lexicon Pharmaceuticals
2.1171 of 5 stars
$1.13
-5.0%
$3.23
+185.4%
-34.4%$432.45M$31.08M-3.42140Analyst Forecast
XOMA
XOMA Royalty
3.857 of 5 stars
$33.77
-1.3%
$69.50
+105.8%
+24.6%$413.40M$28.49M-21.7910Positive News
CBIO
Crescent Biopharma
3.5529 of 5 stars
$14.70
-2.4%
$25.60
+74.1%
N/A$294.42M$10K-0.4250News Coverage
VNDA
Vanda Pharmaceuticals
4.07 of 5 stars
$4.61
-2.9%
$16.50
+257.9%
-8.7%$280.67M$198.77M-4.08290
CDXS
Codexis
3.8917 of 5 stars
$2.68
-6.9%
$11.00
+310.4%
-14.5%$260.42M$59.35M-3.23250
IRWD
Ironwood Pharmaceuticals
4.2683 of 5 stars
$1.27
flat
$4.94
+289.0%
-77.8%$206.29M$351.41M-25.39220Gap Down
SGMO
Sangamo Therapeutics
2.1451 of 5 stars
$0.55
-6.2%
$4.50
+718.2%
-33.6%$176.89M$57.80M-1.90480News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ACHV) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners